3SBIO (01530) shares rose more than 3%, up 3.54% as of press time to HK$32.74, with a turnover of HK$15.4368 million.

On the news front, according to 3SBIO's official WeChat account, on September 28, Zhejiang 3SBIO Mandy Pharmaceutical Co., Ltd. (hereinafter referred to as "Mandy"), a subsidiary of 3SBIO, and Wansheng Pharmaceutical (hereinafter referred to as "Wansheng") announced that they have entered into an exclusive commercialization collaboration with Hangzhou MindRank Technology Co., Ltd. (MindRank, hereinafter referred to as "MindRank") for MDR-001, an AI-designed oral small molecule GLP-1 receptor agonist independently developed by MindRank, covering Mainland China, Hong Kong, and Macau.

MDR-001 is currently undergoing a Phase III pivotal clinical study in China targeting adults with obesity or overweight.

Under the agreement, Mandy and Wansheng Pharmaceutical will pay MindRank up to RMB 150 million in collaboration rights payments (including upfront payment, regulatory approval, first commercial shipment, and additional indication collaboration rights payments), and up to RMB 1.6 billion in royalty payments upon achieving agreed conditions, with the potential total transaction value not exceeding RMB 1.75 billion.